Hsp90β inhibition upregulates interferon response and enhances immune checkpoint blockade therapy in murine tumors
Authors:
Open Access
- 20 October 2022
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 13, 1005045
Abstract
Response resistance to the immune checkpoint blockade (ICB) immunotherapy remains a major clinical challenge that may be overcome through the rational combination of ICB and specific targeted therapeutics. One emerging combination strategy is based on sensitizing ICB-refractory tumors with antagonists of 90kD heat shock protein (Hsp90) that target all four isoforms. However, pan-Hsp90 inhibitors are limited by the modest efficacy, on-target and off-tumor toxicities, and induction of the heat shock response (HSR) that overrides the effect of Hsp90 inhibition. Recently, we developed Hsp90β-selective inhibitors that were cytotoxic to cancer cells but did not induce HSR in vitro. Here, we report that the Hsp90β inhibitor NDNB1182 downregulated CDK4 (an Hsp90β-dependent client protein) and induced the expression of endogenous retroviral elements and interferon-stimulated genes. In syngeneic mouse models of prostate cancer and breast cancer, NDNB1182 significantly augmented the efficacy of ICB therapy. Furthermore, NDNB1182 showed superior tolerability to the pan-Hsp90 inhibitor Ganetespib in mice. Our findings provide evidence that Hsp90β inhibition is a potentially effective and safe regimen to combine with ICB to treat immunotherapy-refractory solid tumors.Keywords
This publication has 70 references indexed in Scilit:
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in CancerNew England Journal of Medicine, 2012
- Development of a Grp94 inhibitorJournal of the American Chemical Society, 2012
- The hERG Channel Is Dependent upon the Hsp90α Isoform for Maturation and TraffickingMolecular Pharmaceutics, 2012
- Kinetics of DNA methylation inheritance by the Dnmt1-including complexes during the cell cycleCell Division, 2012
- The Molecular Chaperone Hsp90α Is Required for Meiotic Progression of Spermatocytes beyond Pachytene in the MousePLOS ONE, 2010
- Targeting the dynamic HSP90 complex in cancerNature Reviews Cancer, 2010
- A small molecule cell-impermeant Hsp90 antagonist inhibits tumor cell motility and invasionOncogene, 2007
- Context-Dependent Hormone-Refractory Progression Revealed through Characterization of a Novel Murine Prostate Cancer Cell LineCancer Research, 2005
- Functional proteomic screens reveal an essential extracellular role for hsp90α in cancer cell invasivenessNature Cell Biology, 2004
- Role of the Cytosolic Chaperones Hsp70 and Hsp90 in Maturation of the Cardiac Potassium Channel hERGCirculation Research, 2003